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Abstract
Background: Toxoplasmosis is a worldwide zoonosis caused by the intracellular parasite Toxoplasma gondii.
However, no effective vaccine is yet available. Poly(lactide-co-glycolide) polymers can reduce protein degradation
and sustain the release of antigens over a long period, which could generate a long-lasting immune response in
vivo. Using a mouse model of toxoplasmosis, we evaluated the protective efficacy of vaccination with two
recombinant proteins, which are formulated in biodegradable polymers.
Methods: Two recombinant proteins, rCDPK6 and rROP18, were encapsulated in poly(D,L-lactide-co-glycolide)
(PLG), and then injected subcutaneously into Kunming mice. The mice immune responses were evaluated in terms
of lympho-proliferation, cytokine expression, and antibodies. The survival of infected mice and brain cyst formation
were also evaluated at 6 weeks after challenge with T. gondii RH strain (genotype I) or PRU strain (genotype II).
Results: Both protein vaccines induced Th1-biased immune responses, with increased specific antibodies and T
cells, high levels of interferon-γ and interleukin 2, and strong lymphocyte proliferative responses. The mice
immunized with the various protein vaccines survived slightly longer time than the control groups (P > 0.05) after
injection with T. gondii RH strain. There were fewer brain cysts in the mice in all the immunized groups than that in
the control groups, and the brain cysts were significantly reduced in mice immunized with proteins + 206,
rCDPK6 + PLG and rCDPK6 + rROP18 + PLG (P < 0.05) compared controls. Further comparison of the immune
responses to the proteins adjuvanted with PLG or Montanide™ ISA 206 VG 6 weeks after the last immunization
revealed that antigens encapsulated in PLG conferred greater protective immunity against challenge.
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Conclusions: These findings suggest that the two recombinant T. gondii proteins encapsulated in PLG conferred
immunity to T. gondii for an extended period, providing the foundation for the further development of a
commercial vaccine against toxoplasmosis.
Keywords: Toxoplasma gondii, Toxoplasmosis, Rhoptry protein 18, Calcium-dependent protein kinase 6, Protein
vaccine, PLG microparticles
Background
As the most successful parasitic pathogen, Toxoplasma gon-
dii infects a wide range of warm-blooded vertebrate inter-
mediate hosts, including humans [1–3]. The parasite is
one of the most common pathogens of humans, and
nearly one third of the global population is chronically
infected [3, 4]. In general, Toxoplasma gondii infections
are asymptomatic in immunocompetent individuals, but
sometimes infected individuals manifest mild flu-like
symptoms [3]. Congenital toxoplasmosis can cause ocular
disease, intracranial calcification, hydrocephaly, micro-
cephaly, and psychomotor and mental retardation in in-
fants of women who experienced primary infection with
T. gondii during gestation [5–7]. The clinical presentation
of toxoplasmosis can also be severe in immunosuppressed
individuals [3]. T. gondii infection is frequently reported in
many domesticated animals in China [8–10], and causes
abortion and neonatal loss, especially in goats and sheep
[3]. The reemergence of food-borne routes of T. gondii
transmission to humans has raised public health and food
safety concerns in recent years [2, 4, 11].
The development of vaccine strategy against T. gondii
infection is a public health priority because there are no
effective chemical drugs to eliminate the parasite cysts
[12, 13], and only a live-attenuated vaccine is available for
veterinary use, based on the S48 strain of T. gondii (Toxo-
vax®), has been licensed to prevent abortion in sheep [14].
Although this licensed vaccine against the parasite is rec-
ognized as a milestone in T. gondii vaccine studies, the
safety of live-attenuated tachyzoites for humans and food-
producing animals is uncertain due to virulence reversion
or possible pathogenicity in individuals with compromised
immune systems [13, 15]. Therefore, the development of
more effective, practical, and safe vaccines against T. gon-
dii infection for use in humans and animals is necessary.
Recombinant subunit vaccines may offer an efficient,
safe and alternative way to immunize humans, and have
been widely used to evaluate the immunogenicity of T.
gondii antigens [13, 16–18]. The rhoptry protein ROP18
is one of the key virulence factors in the pathogenesis of
T. gondii infection, controlling the intracellular prolifera-
tion of the parasite, and induces a protective effect
against toxoplasmosis in mice. Therefore, it is consid-
ered a promising candidate vaccine against infection by
this pathogen [19–21].
The calcium-dependent protein kinases (CDPKs) are a
distinct protein kinase family restricted to plants, cili-
ates, and apicomplexans [22, 23]. Several members of
the CDPK family have been identified in T. gondii, which
participate in regulation of some critical biological pro-
cesses in the parasite, including cell invasion, egress, and
division [24, 25]. In previous studies, we demonstrated
that the TgCDPK1 [26] and TgCDPK3 genes [27] are
promising candidates for the development of vaccines
against T. gondii infection, and the TgCDPK5 protein
elicited only partial protection against chronic parasitic
infection [28]. However, the immunogenicity of other
members in the family has not been comprehensively
evaluated.
Poly(lactide-co-glycolide) (PLG) polymers are a safe
delivery system for antigens that can reduce protein deg-
radation, sustain the release of antigens over a long
period [29], and generate a long-lasting immune re-
sponse in vivo, as revealed in previous studies, including
T. gondii vaccines [13].
In order to identify effective vaccine candidates against
both acute and chronic infection of T. gondii through
combination of various proteins, a novel CDPK family
member in T. gondii, designated TgCDPK6, was mixed
with TgROP18 protein and the protective efficacy of this
antigenic mixture against acute and chronic toxoplasmosis
was evaluated. Additionally, the proteins were encapsu-
lated in PLG microparticles and the performance of this
sustained release formulation was evaluated. The sus-
tained release of the newly combined candidate vaccines
for an extended period is a step forward in the develop-
ment of a commercial vaccine against T. gondii infection.
Methods
Mice
Specific-pathogen-free female Kunming mice (6–8 weeks
old) were purchased from the Center of Experimental An-
imals, Lanzhou University, Lanzhou, China. All the mice
were handled in strict accordance with the Good Animal
Practice requirements of the Animal Ethics Procedures
and Guidelines of the People’s Republic of China.
Parasites
Tissue cysts of the low-virulence PRU strain (type II)
and tachyzoites of the high-virulence RH strain (type I)
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of T. gondii were propagated and harvested as described
in our previous studies [27, 28], and were used for the in
vivo challenge of mice. The tachyzoites obtained were
also used for total RNA extraction (RNAprep Pure Tis-
sue Kit, Sangon, China) and the preparation of soluble
tachyzoite antigens, as previously described [30].
Expression and purification of recombinant proteins in E.
coli
The complete open reading frames of the TgCDPK6 and
TgROP18 genes were amplified with one-step reverse
transcription–PCR (RT–PCR), using two pairs of spe-
cific primers, TgROP18: 5’-CGGGATCCATGTTTTCGG
TACAGCGGCCA-3’ (forward) and 5’-GCGTCGACTT
ATTCTGTGTGGAGATGTTCCTG-3’ (reverse) contain-
ing BamH I and Sal I restriction sites (italic), respectively;
TgCDPK6: 5’-CCGGGTACCATGGACGATCCTGCGAA
CTTCCGA-3’ (forward) and 5’- CGCGCGGCCGC
TTAGTCGTGGCGCATATACGCGAC-3’ (reverse) con-
taining Kpn I and Not I restriction sites (italic),
respectively.
The two obtained RT–PCR products were inserted
into the prokaryotic expression vector pET-30a(+) via
their restriction sites, forming pET-ROP18 and pET-
CDPK6, respectively. Escherichia coli strain BL21(DE3)
was transformed with pET-ROP18 and pET-CDPK6,
respectively and the expression of each recombinant
protein was induced with 0.6 mmol/L isopropyl β-D-1-
thiogalactopyranoside (Sangon), with shaking for 8 h at
26 °C. The recombinant bacteria were sonicated on ice
at 400 W/s after three freeze–thaw cycles and then cen-
trifuged at 10,000 × g for 30 min at 4 °C. The rROP18
and rCDPK6 proteins were purified through an Ni2+ col-
umn (Novagen, USA), according to the manufacturer’s
instructions. The samples were analyzed with sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE).
Polyclonal antibodies (pAbs)
The purified rROP18 and rCDPK6 proteins were each di-
luted to 500 μg/mL with PBS. Polyclonal antibodies
against each protein were raised by injecting rabbits with
each protein (200 μl) three times at two-week intervals.
Two weeks after the last immunization, blood samples
were collected from the rabbits’ ear arteries. The antibody
titers were determined with enzyme-linked immunosorb-
ent assays (ELISAs) using horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG (diluted 1:5000; Sigma,
USA) as the secondary antibody. Serum from a rabbit
treated with PBS was used as the negative control.
Microparticle preparation
The rTgCDPK6 and rTgROP18 proteins were each en-
capsulated in 50:50 PLG (Sigma) using the water-in-oil-
in-water double emulsion solvent evaporation technique,
according to a previous study, with minor modifications
[31]. In brief, 2 mg of each protein was dissolved in 2 ml
of PBS and mixed with 2 ml of 10 % polymer in dichlo-
romethane (Sigma) to form a water-in-oil emulsion. The
emulsion was then homogenized with 7 ml of 2.5 %
polyvinyl alcohol (Sigma) solution to generator a stable
water-in-oil-in-water double emulsion. The microparti-
cles were collected by centrifugation at 4000 × g for
30 min and washed three times with distilled water to
remove any non-encapsulated protein.
Protein encapsulation
rCDPK6 + PLG and rROP18 + PLG microparticles
(50 mg) were dissolved in 500 μL of 0.1 M NaOH with
2.5 % SDS at 37 °C for 4 h to extract the encapsulated
proteins [29]. The reaction was terminated by adding
500 μl of HCl (0.1 M). The mixture was then centrifuged
at 12,000 × g for 10 min and each supernatant was used to
assess the content of the two proteins with a UV–visible
light spectrophotometer (Thermo Scientific) as the ab-
sorbance at 280 nm (A280) and calibrated to empty PLG
microparticles. The actual ratio (w/w) of each protein en-
capsulated in the microparticles was determined and the
encapsulation efficiency (%) was calculated with the for-
mula: (actual protein encapsulation)/(theoretical protein
encapsulation) × 100 % [29]. All measurements were made
in triplicate on samples from different batches.
Duration of protein release in vitro
The microparticles (5 mg) of rCDPK6 + PLG, rROP18 +
PLG and rCDPK6 + rROP18 + PLG were each suspended
in 1 ml of PBS and were shaken at 37 °C in 2 ml Eppen-
dorf tubes for 35 days. The A280 values for the sampled
supernatants were determined daily with a UV–vis spec-
trophotometer (Thermo Scientific). The supernatants
were added back into tubes and shaken. At 1, 7, 14, 21,
28, and 35 days, the supernatants were collected in new
tubes for a western blot analysis, detected by the
protein-specific rabbit pAbs. In the SDS-PAGE analysis,
the loading volumes of the protein solutions in each well
were identical.
Immunization and challenge
A total of 13 groups of mice were injected subcutane-
ously with 10 μg of each protein. The vaccinated mice
were immunized with rCDPK6, rROP18, rCDPK6 +
rROP18, rCDPK6 +Montanide™ ISA 206 VG (206),
rROP18 + 206, rCDPK6 + rROP18 + 206, rCDPK6 + PLG,
rROP18 + PLG, or rCDPK6 + rROP18 + PLG, and the
groups were designated according to the different vac-
cines. Mice receiving PBS alone, PBS + 206, PBS + PLG,
or non-treated with anything were used as controls.
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Six weeks after the second immunization, 10 mice in
each group were challenged intraperitoneally with 103
tachyzoites of the T. gondii RH strain, and their survival
was recorded daily until all the mice had died. Six mice
in each group were inoculated orally with 10 PRU tissue
cysts, and their brain cysts were determined 4 weeks
after chronic infection was established.
Antibody assays
At weeks 0, 2, and 8, serum samples from each group
were collected from the mouse tail veins to evaluate the
production of specific antibodies using indirect ELISAs.
The wells of 96-well microtiter plates were coated with
rCDPK6 (10 μg/mL), rROP18 (10 μg/mL), or a mixture
of the two proteins (each of 10 μg/mL). The nonspecific
binding sites were blocked with TBS (150 mmol/L NaCl,
10 mmol/L Tris–HCl) containing 5 % bovine serum al-
bumin. Sera (diluted 1:50) from the immunized mice
were added to the wells coated with the corresponding
proteins and incubated at 37 °C for 1 h. The plates were
then washed by TBST (TBS + 0.05 % Tween 20) at 5
times. Each well was then incubated with HRP-
conjugated anti-mouse IgG (diluted 1:250). After added
200 μl substrate solution (80 μg of 3,3′,5,5’-tetramethyl-
benzidine, 30 % H2O2) was added, the reaction was
stopped with 2 M H2SO4. Both positive and negative
controls were included in each plate. All measurements
were made in triplicate at an absorbance of 450 nm.
Lymphocyte proliferation assay
The proliferative activity of the splenocytes from
each mouse group was measured with the 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) method, according
to our previous study [30]. The splenocytes were cultured
in triplicate at a density of 2 × 105 cells per well in
complete medium (Dulbecco’s modified Eagle’s medium +
10 % FCS + 100 U/ml penicillin/streptomycin). For the
tests, the cells were stimulated with the corresponding an-
tigens (A, 10 μg/ml), and cells to which medium (M)
alone was added were used as the negative control. The
stimulation index (SI) was calculated with the for-
mula: SI = OD570A/OD570M.
Flow cytometry
The percentage of CD4+ T cells and CD8+ T cells present
in the spleens were determined by using flow cytometry
according to our previous study [30]. The CD3, CD4, and
CD8 antigens on the surfaces of the T-cell subclasses were
stained with the corresponding anti-mouse antibodies
(eBioscience) tagged with phycoerythrin (PE), allophyco-
cyanin (APC), and fluorescein isothiocyanate (FITC), re-
spectively. The fluorescence profiles of all the samples
were analyzed on a FACScan flow cytometer (BD Biosci-
ences) using the System II Software (Coulter).
Cytokine assays
The levels of cytokines secreted by the cultured splenocytes
were measured with commercial ELISA kits (BioLegend,
USA), as described in previous studies [13, 30]. The ana-
lyses were performed in triplicate.
Statistical analysis
All statistical analyses were performed in GraphPad Prism
5.0 or SAS (Statistical Analysis System, version 8.0). The
differences in antibody responses, lympho-proliferation
assays, cytokine production, and percentages of CD4+ and
CD8+ T cells were compared with one-way ANOVA.
Differences in the comparisons of groups were considered
significant at P < 0.05.
Results
Expression of rCDPK6 and rROP18 proteins
Escherichia coli BL21(DE3) cells were transformed with
either the prokaryotic expression vector pET-CDPK6 or
pET-ROP18. Each recombinant protein was separated
with SDS-PAGE and visualized with Coomassie Brilliant
Blue staining.
Protein encapsulation rate and release rate from
microparticles in vitro
The encapsulated proteins were extracted with NaOH.
After centrifugation, the supernatants were analyzed
with a UV–Vis spectrophotometer (Thermo Scientific).
The encapsulation efficiency for the rCDPK6 protein
ranged from 57.3 % to 67.7 % and that for the rROP18
protein ranged from 58.1 % to 72.3 %. There were no
significant differences (P > 0.05) among the three batches
of each type of microparticle.
The concentrations of the rCDPK6 and rROP18 pro-
teins released from each type of microparticle were tested
daily until day 35. The rCDPK6 and rROP18 proteins
were released gradually from the microparticles. At day 5,
about 70 % of each protein was still loaded in the micro-
particles, and nearly 30 % of each protein was rapidly re-
leased in week 5. Altogether, more than 80 % of each
protein was released over the 35 days of the study (Fig. 1).
The antigenicity of the released rCDPK6 and rROP18
proteins collected on days 1, 7, 14, 21, 28, and 35 were
determined by western blotting. The released proteins
were identified by their corresponding specific Abs, sug-
gesting the potential capacity of the PLG-encapsulated
antigens to elicit protective immunity against T. gondii
infection in the long term.
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Antibody responses
Three serum samples from each vaccinated mouse group
were collected at 0, 2, and 8 weeks to detect specific IgG
antibodies. All the protein vaccines elicited specific humoral
responses and the levels of IgG antibodies in the experi-
mental mice increased sequentially with successive immuni-
zations with the tested antigens, and reached their highest
levels in week 8 (Fig. 2). However, no significant differences
in the antibody levels were detected between pre- and post-
immunization in the control groups. Six weeks after the last
vaccination, the levels of IgG antibodies in the mice immu-
nized with rROP18 + PLG or rCDPK6 + rROP18 + PLG
were significantly higher than those in the mice immunized
with rROP18 or rCDPK6 + rROP18 (P < 0.01), but were not
statistically different from those in the mice immunized
with various proteins + 206 adjuvant (P > 0.05) (Fig. 2).
Evaluation of splenocyte proliferation
The proliferative responses of splenocytes from all
mouse groups were tested with ELISAs after they had
been co-cultured with MTS for 96 h. The splenocytes
proliferated more strongly in the vaccinated mice than
in the controls (Fig. 3), and the highest proliferative re-
sponse was detected in the mice immunized with
rCDPK6 + rROP18 + PLG (P < 0.001). The proliferation
SIs of the four control groups did not differ significantly
(P > 0.05).
Percentages of CD4+ and CD8+ T lymphocytes
The percentages of CD4+ and CD8+ T cells in the total
splenocytes in each group were determined with flow cy-
tometry, and the results are shown in Fig. 4. Mice immu-
nized with the various protein vaccines generated higher
Fig. 1 Detection of rCDPK6 and rROP18 proteins release from PLGs in vitro
Fig. 2 IgG antibodies induced by various protein vaccines in the sera of mice at 0, 2, and 8 weeks. Each bar represents the mean OD (± SE, n = 3).
*P < 0.05, **P < 0.01 compared with the controls. NS: not significant
Zhang et al. BMC Infectious Diseases  (2016) 16:168 Page 5 of 11
levels of both T-cell subtypes than those in the controls.
Immunization of mice with protein–PLG microparticles
induced significantly higher levels of CD4+ (P < 0.001) and
CD8+ T lymphocytes (P < 0.01) than did the controls.
The percentages of CD4+ cells in mice immunized
with rROP18 + 206 and rROP18 + PLG were signifi-
cantly higher than that in controls (P < 0.05). Only
mice from rROP18 + 206 group were showed signifi-
cantly higher level of CD8+ T cells compared to that
in controls (P < 0.05).
Cytokine production by spleen cells
The effects of immunization on cytokine production in
vitro after stimulation with specific antigens were inves-
tigated with ELISAs. As shown in Table 1, the
immunization of mice with various proteins significantly
increased the production of interferon-γ (IFN-γ; P <
0.05) and interleukin-2 (IL-2; P < 0.05). In contrast, the
levels of cytokines IL-4 and IL-10 were significantly re-
duced compared with those in the control groups (P <
0.05). The levels of IL-12 in mice vaccinated with each
protein did not differ significantly from those in the con-
trols (P > 0.05).
Protective activity of vaccination with protein antigens
At 6 weeks after vaccination, 10 mice from each group
were challenged with 103 tachyzoites of the T. gondii RH
strain and 10 cysts of the PRU strain. The average sur-
vival time of the mice immunized with the various pro-
tein vaccines (8.56 days) was slightly longer than that in
the controls (8 days) (Fig. 5). Immunization with
rROP18 + PLG (10.9 days ± 2.58), rROP18 (10.1 days ±
1.52), and rCDPK6 + PLG (9.1 days ± 0.24) was showed
to significantly prolong the average survival time in mice
compared with that of the controls after challenged with
RH strain (P < 0.05).
As shown in Figure 6, immunization with the different
proteins partially protected the mice against chronic T.
gondii infection. The tissue cyst loadings in the brains of
mice vaccinated with the various proteins varied from
47.7 % to 73.6 %, and were significantly lower than those
in the control groups (P < 0.001). The protein antigens
plus PLG microparticles provided more effective pro-
tection to the mice than was observed in the corre-
sponding groups of mice immunized only with
proteins. However, the differences were not statisti-
cally significant (P > 0.05).
Discussion
In this study, vaccination with the rROP18 or rCDPK6
protein induced specific humoral and cellular immune
responses. Infected vaccinated mice showed slightly im-
proved survival time and reduced brain cyst burden. These
results suggest that these two recombinant T. gondii anti-
gens are attractive targets for further validation and that
PLG maintains the immunogenicity of the encapsulated
proteins.
Recombinant protein vaccines have been used in nu-
merous immunological studies in veterinary medicine in
recent years [13] because they can induce systemic
humoral and cellular immune responses [32–35] and are
amenable to large-scale production. However, recombin-
ant proteins can be easily proteolytically degraded in the
vaccinated animals, which necessitate more frequent im-
munizations. Microparticles of PLG, a biodegradable and
biocompatible polymer, can protect proteins from
Fig. 3 Splenocyte proliferative responses in immunized mice. *P < 0.05. ** P < 0.01
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degradation for long periods [36]. The sustained release
of these antigens should facilitate their uptake by
antigen-presenting cells, which would elicit a strong im-
mune response [37]. When PLG was used as a delivery
system to evaluate the protective efficacy of anti-Toxo-
plasma vaccines, significantly long-lasting immune re-
sponses and effective protection against T. gondii
infection were induced in vaccinated mice [38, 39]. Here,
we immunized mice with protein vaccines twice, and the
proteins encapsulated in PLG microspheres elicited
stronger humoral and cellular immune responses com-
pared to the control mice. Also, vaccination using en-
capsulated proteins maintained the protective activity
for 6 weeks after the last immunization. This suggests
that PLG may be an attractive alternative to develop
long-lasting vaccines against T. gondii infection in
humans and animals.
Toxoplasma gondii ROP18 protein is considered a
promising candidate target for vaccination against acute
toxoplasmosis in mice [16, 19], and a specific CD8+ T-cell
response against TgROP18-derived peptides has also been
observed in patients with chronic asymptomatic toxo-
plasmosis, suggesting the potential immunogenicity of
TgROP18 in patients with chronic toxoplasmosis [40].
Our previous study predicted 10 potential epitopes dis-
tributed on TgCDPK6, indicating that it is a potential vac-
cine antigen against T. gondii [41]. Here, mice immunized
with rCDPK6 produced high levels of IgG antibodies and
a strong lymphoproliferative response compared with
those of the controls. In a chronic infection model, the
brain cyst burden in rCDPK6-immunized mice was re-
duced by more than 40 % compared to the level in the
controls. Together with the results for TgROP18, these
findings suggested that these two proteins (TgROP18 and
Fig. 4 Percentages of T-cell subsets (a CD4+; b CD8+ T cells) in immunized mice. The 4 control groups, PBS + PLG, PBS + 206, PBS and blank
control, were treated as controls in statistical analysis. The P value was calculated using the measurements from each immunized group to
compare with the average from controls. Furthermore, the proteins + PLG, proteins + 206 and proteins alone were respectively treated as a group
compared with the average from controls. **P < 0.01. *** P < 0.001. NS: not significant
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TgCDPK6) may be used in recombinant multi-antigen
vaccines against T. gondii infection.
Th1 immunity has been shown to play a critical role
in the host’s defenses against intracellular pathogens,
primarily via an IFN-γ-driven cytotoxic T-cell (CTL) re-
sponse [42]. IFN-γ, produced by natural killer (NK) cells
and T cells, plays a crucial role in host survival because
it promotes multiple intracellular mechanisms that
constrain the replication of the parasite (e.g., nitric
oxide) [43–47] or even kill T. gondii. IFN-γ-deficient
mice showed extreme susceptibility to infection with the
parasite [48]. IFN-γ combined with IL-2 is also involved
in preventing parasitic invasion [49]. Another character-
istic cytokine of Th1 immunity is IL-12, an innate prod-
uct of the host’s Toll-like receptor/MyD88 response after
T. gondii infection [50]. IL-12 is an important effector,
Table 1 Cytokine production by splenocytes of immunized Kunming mice after stimulation with toxoplasma lysate antigena
Group Cytokine production (pg/ml)
IFN-γ IL-2 IL-4 IL-10 IL-12 (p70)
CDPK6 + ROP18 + PLG 2092.66 ± 363.69*** 238.48 ± 6.37*** >0* 360.61 ± 296.21 4.55 ± 2.91
CDPK6 + ROP18 + 206 1727.43 ± 506.06** 257.92 ± 4.04*** >0* 520.98 ± 91.89*** <0
CDPK6 + ROP18 1835.37 ± 384.89** 251.35 ± 5.51*** >0* 409.57 ± 337.62 <0
ROP18 + PLG 1720.61 ± 329.18** 243.76 ± 91.02** >0* 56.92 ± 57.09*** 9.17 ± 15.2
ROP18 + 206 1595.37 ± 1204.87 263.7 ± 30.02*** >0* 430.08 ± 623.13 <0
ROP18 1530.8 ± 724.92* 244.52 ± 1.82*** >0* 484.58 ± 453.58 <0
CDPK6 + PLG 1040.08 ± 477.05 179.65 ± 107.16 >0* 139.41 ± 141.62 >0
CDPK6 + 206 1013.52 ± 630.91 215.95 ± 43.12*** >0* 121.55 ± 103.54 <0
CDPK6 838.58 ± 186.37 85.66 ± 140.77 >0* >0 <0
PBS + PLG 471.15 ± 232.97 45.11 ± 46.95 9.29 ± 3.56 609.99 ± 267.23 6.12 ± 7.25
PBS + 206 611.01 ± 308.16 38.89 ± 35.46 13.09 ± 4.67 613.01 ± 154.41 1.09 ± 2.26
PBS 515.27 ± 363.03 20.76 ± 32.26 14.73 ± 2.46 597.48 ± 216.81 <0
Control 590.3 ± 257.92 33.9 ± 13.16 12.43 ± 12.92 606.35 ± 376.32 <0
a Splenocytes from mice were harvested 6 weeks after the last immunization
The 4 control groups, PBS + PLG, PBS + 206, PBS, and blank control, were treated as controls in regard to statistical analysis. *P < 0.05. **P < 0.01. ***P < 0.001
compared with the average of the controls
Fig. 5 Survival rates of mice immunized with various protein vaccines after challenge with Toxoplasma gondii. Kunming mice were challenged
with 1 × 103 tachyzoites of Toxoplasma gondii RH strain, 6 weeks after the second immunization
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and only mediates the adaptive immune response, thus
participating in the regulation of IFN-γ [51]. All the pro-
teins investigated in the present study induced a signifi-
cant increase in cytokines INF-γ and IL-2, which are
essential for the prolonged survival and reduced brain
cysts in the immunized mice. The mixed-antigen vaccine
produced higher levels of INF-γ and IL-2 than either
protein alone. In contrast, IL-4 and IL-10, Th2-based cy-
tokines, were reduced in the immunized mice. These re-
sults suggest that the cellular immune responses
induced by the two protein antigens were primarily
skewed to a Th1-predominant immune response.
CD8+ T cells are specialized to recognize and destroy
infected host cells by the production of IFN-γ or
perforin-mediated cytolysis [52, 53], which are also crit-
ical in mediating the resistance to T. gondii infection.
CD8+ T cells that mediate this protection should com-
bine with CD4+ T cells to play a synergistic role [53, 54].
In the protein-immunized mice, both T-cell subsets were
increased compared with those in the controls. This ten-
dency is consistent with the results of Th1-type cyto-
kines, especially IFN-γ, and is consistent with the
mechanisms underlying the protective effects of these
vaccines.
The IgG antibodies specifically directed against T. gondii
opsonize the parasite for phagocytosis, block invasion, and
are also related to the activation of the classical comple-
ment pathway in those who are acutely susceptible to
toxoplasmosis [55, 56]. Mice vaccinated with the proteins
in this study displayed higher specific IgG antibody titers
than the controls, and the IgG antibody titers were espe-
cially high in the group immunized with rCDPK6 +
rROP18 plus PLG, which may have contributed to the sig-
nificant reduction in tissue cyst burden in the brains of
this group.
Immunization with a recombinant multi-antigen vac-
cine showed a slightly increased average survival
(8.56 days) compared the controls, which died within
8 days of challenge with T. gondii (P > 0.05). TgROP18 and
TgCDPK6 have the advantage of protecting against acute
and chronic toxoplasmosis, respectively, but when the two
recombinant proteins were mixed, the effect against acute
T. gondii infection showed no synergistic effect, contrary
to our expectation. In addition to increasing the numbers
of CTL epitopes and detecting new T. gondii antigens, as
we noted previously [13], the immunization strategies and
the ratio of each antigen in the mixed protein vaccine
should be evaluated in future studies.
Conclusions
Our study demonstrated that vaccination of mice with
rCDPK6 can elicit Th1-biased responses against acute
and chronic T. gondii infections. However, a combin-
ation with rROP18 did not enhance the immune re-
sponses or provide better protective efficacy against T.
gondii infection compared to each single protein. Encap-
sulation of proteins in PLG maintains the immunogen-
icity for a longer period. Evaluation of the potential of
PLG in the development of a vaccine against toxoplas-
mosis should be further studied.
Fig. 6 Number of tissue cysts per brain after challenge with Toxoplasma gondii cysts in mice from all groups. Mice immunized with various
protein vaccines and in controls were challenged with 10 tissue cysts of T. gondii PRU strain, 6 weeks after the last booster. The 4 control groups,
PBS + PLG, PBS + 206, PBS and blank control, were treated as controls in statistical analysis. The P value was calculated using the measurements
from each immunized group to compare with the average from controls. Furthermore, the numbers of brain cysts in mice immunized with
various proteins were compared with that in controls. ***P < 0.001
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